Loading…
Develops antibody and immune-based therapies for infectious diseases and cancer.
Develops antibody and immune-based therapies for infectious diseases and cancer.
Has no approved product on sale, so it is funded by cash built up while its COVID antibody sold, plus occasional partner or grant income. Spending goes on trials, which means results hinge on study readouts rather than sales.
Moat: none (IP / patents). Broad antibody engineering platform but past reliance on a discontinued COVID antibody; no current approved product.
Headquarters: San Francisco, California, US · Founded: 2016 · Employees: 367
Size Vir Biotechnology (VIR) is a United States Health Care company (Biotechnology) with a market value of $2.07B, the 1771st largest of 3,117 United States companies the cockpit tracks. Shares closed at $12.21 on 6 Nov 2026.
Performance Over six months the shares gained 33.9%, against +20.0% for the median peer and -1.1% for the United States market (cap-weighted) — 9th highest of 21 in its peer set.
Growth Revenue grew 1,495.9% over the last twelve months (peer median +23.2%); the operating margin is -92.2% (peer median 7.5%).
Valuation It trades at 5.4× enterprise value to sales against a peer median of 9.3× (4th cheapest of 14).
Capital Return on invested capital runs 53.8 points below its cost of capital (13.0% WACC).
Short interest Short interest is 9.6% of the free float (15 Oct 2026).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $303M | $68.6M | $74.2M | $86.2M | $1.62B |
| Revenue growth | — | -8% | -14% | -95% | — |
| Gross profit | $292M | $56.9M | $58.8M | $64.0M | $1.45B |
| EBITDA | -$268M | -$456M | -$509M | -$642M | $849M |
| Net income | -$252M | -$438M | -$522M | -$615M | $516M |
| Free cash flow | -$204M | -$397M | -$454M | -$800M | $1.60B |
| Capital expenditure | $1.09M | $4.83M | $7.30M | $21.6M | $68.0M |
| Total debt | $93.3M | $97.9M | $97.9M | $125M | $128M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Vir Biotechnology VIR | $2.07B | +34% | +1,496% | -92% | 5.4× | n/a |
| Gilead Sciences GILD | $207B | +28% | +7% | 38% | 7.2× | -2.9% |
| GSK GSK.L | $102B | 0% | +4% | 25% | 2.9× | -0.1% |
| Regeneron Pharmaceuticals REGN | $93.5B | +27% | +19% | 30% | 5.2× | -2.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | VIR | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +9.8% | +1.3% | 8th highest of 21 |
| 6-month return | +33.9% | +20.0% | 9th highest of 21 |
| Distance from 52-week high | -1.9% | -25.8% | 3rd highest of 21 |
| Revenue growth (TTM) | +1,495.9% | +23.2% | 2nd highest of 16 |
| Operating margin | -92.2% | 7.5% | 2nd lowest of 15 |
| EV / Sales | 5.4× | 9.3× | 4th cheapest of 14 |
| ROIC minus cost of capital | -53.8 pp | -6.4 pp | 3rd lowest of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Vir Biotechnology VIR | United States | $2.07B | +34% | +1,496% | -92% | 5.4× | n/a | n/a |
| Replimune REPL | United States | $2.05B | +547% | n/a | n/a | n/a | n/a | n/a |
| Trevi Therapeutics TRVI | United States | $2.04B | -1% | n/a | n/a | n/a | n/a | n/a |
| Shenzhen Kangtai Biological Products 300601.SZ | China | $2.11B | -9% | -9% | 6% | 5.6× | 25.3% | +3.4% |
| Hitgen 688222.SS | China | $2.12B | +23% | +42% | 27% | 19.1× | 38.7% | +16.8% |
| First Tracks Biotherapeutics TRAX | United States | $2.01B | +145% | n/a | n/a | n/a | n/a | n/a |
| GemPharmatech 688046.SS | China | $2.01B | +59% | +25% | 22% | 13.3× | 35.7% | +24.8% |
| Vera Therapeutics VERA | United States | $2.15B | -18% | n/a | n/a | n/a | n/a | n/a |
| BioCryst Pharmaceuticals BCRX | United States | $1.97B | -11% | +60% | 42% | 2.5× | -10.6% | +117.9% |
| Maravai Lifesciences MRVI | United States | $1.95B | +108% | -3% | -13% | 9.3× | n/a | n/a |
| Lakefront Biotherapeutics LKFT.AS | Netherlands | $2.19B | +25% | +259% | 60% | n/a | n/a | n/a |
| Alamar Biosciences ALMR | United States | $1.95B | +17% | +195% | -42% | 23.6× | n/a | n/a |
| Recursion Pharmaceuticals RXRX | United States | $2.19B | +6% | +56% | -725% | 25.1× | n/a | n/a |
| Aurinia Pharmaceuticals AUPH | United States | $2.21B | +8% | +21% | 45% | 5.5× | 5.1% | +41.4% |
| Immunome IMNM | United States | $2.21B | -17% | -100% | n/a | n/a | n/a | n/a |
| SKBS 302440.KS | South Korea | $2.22B | -11% | +23% | -25% | 4.5× | n/a | n/a |
| Alvotech ALVO | United States | $1.90B | +49% | -12% | 9% | 6.5× | n/a | n/a |
| Sinocelltech 688520.SS | China | $2.25B | -23% | -40% | -75% | 15.6× | n/a | n/a |
| Vimian VIMIAN.ST | Sweden | $2.26B | +41% | +8% | 19% | 4.9× | 12.5% | +44.5% |
| Septerna SEPN | United States | $2.28B | +105% | +13,520% | -57% | 19.5× | 18.7% | n/a |
| Hemab Therapeutics COAG | United States | $2.29B | +95% | n/a | n/a | n/a | n/a | n/a |